The prognosis is a professional term that refers to the outcome of treatment, which is the most important issue for patients. Prognosis of advanced gastrointestinal mesenchymal tumor The so-called advanced gastrointestinal mesenchymal tumor includes two types of patients: 1. 2. They are patients who have already had their tumors removed and then have recurrence. For a patient with advanced tumor, the outcome of treatment is usually disappointing. For example, in the case of patients with advanced gastric cancer, even with treatment including chemotherapy, radiotherapy, Chinese herbal medicine and biological therapy, the average (median) survival time is usually hardly more than 1 year, and in the case of individuals, it is hardly more than 3 years. However, according to a randomized, multicenter clinical study in the United States and Finland (B2222), the mean (median) survival time for advanced gastrointestinal mesenchymal tumors was 57 months, with a 9-year survival rate of 35%. Therefore, it is important for patients with advanced gastrointestinal mesenchymal tumors to have enough self-confidence to cooperate with treatment, even in advanced stages, in order to achieve a good outcome! Prognosis of resectable gastrointestinal mesenchymal tumors If resectable at the time of first diagnosis, the prognosis is definitely better than the above mentioned advanced gastrointestinal mesenchymal tumors. Before imatinib, a targeted drug, was used to treat mesenchymal tumors, the average (median) survival time for all patients with resectable gastrointestinal mesenchymal tumors was 66 months (note: just 9 months longer than the above results for patients with advanced stages on imatinib), with a 5-year survival rate of 54%, so doctors have found that surgery alone does not cure all patients. Based on the good results obtained with imatinib for advanced gastrointestinal mesenchymal tumors, this drug is again being used in a subset of patients with surgically resected gastrointestinal mesenchymal tumors with the aim of reducing recurrence and prolonging the survival time of patients. According to a randomized multicenter clinical study (SSGVXIII/AIO) including nearly 400 patients with surgically resected gastrointestinal mesenchymal tumors in 24 hospitals in four European countries, the overall 5-year survival rates were 92% (3 years on imatinib after surgery) and 81.7% (1 year on imatinib after surgery). And it should be noted that the patients mentioned above are patients with relatively large tumors, relatively high nuclear division and high risk of recurrence with intraoperative tumor rupture, whereas patients with resectable gastrointestinal mesenchymal tumors who are judged to have a very low, low or intermediate risk of postoperative recurrence based on pathological findings have a better prognosis and can be considered to be cured (if their luck is not so bad).